Skip to main content

Table 2 All secondary care costs of patients with COPD in Denmark 2016 specified on the diagnosis registered with each cost

From: Healthcare costs of patients with chronic obstructive pulmonary disease in Denmark – specialist care versus GP care only

COPD care level five years back: GP care only (reference) Specialist care at least once Comparison
Primary diagnosis (ICD10 codes) registered with the costs Cost total in 1000 Costs / pt. year in % Cost total in 1000 Costs / pt. year in % CoefAdj (95%CI)
Total (any diagnosis) 211,725 3,141 100 395,158 9,047 100 2.81(2.81–2.81)
Respiratory (J*) 23,681 351 11.2 186,975 4,281 47.3 12.0(12.0–12.0)
Cardiovascular (I*) 38,021 564 18.0 40,417 925 10.2 1.58(1.58–1.58)
Factors and contacts (Z*) 31,209 463 14.7 32,275 739 8.2 1.59(1.59–1.59)
Symptoms and findings, NEC (R*) 16,029 238 7.6 24,608 563 6.2 2.31(2.31–2.32)
Neoplasm (C* & D00-D48) 27,700 411 13.1 22,247 509 5.6 1.24(1.24–1.24)
Gastrointestinal (K*) 14,376 213 6.8 16,639 381 4.2 1.76(1.76–1.76)
Infection (A*) 9,106 135 4.3 15,256 349 3.9 2.45(2.45–2.45)
Trauma, outer causes (S*) 10,535 156 5.0 12,170 279 3.1 1.63(1.63–1.63)
Musculoskeletal (M*) 13,875 206 6.6 10,764 246 2.7 1.19(1.19–1.19)
Urology (N00-N51) 6,453 96 3.0 9,559 219 2.4 2.13(2.13–2.13)
Endocrine metabolic (E*) 5,529 82 2.6 7,542 173 1.9 2.00(2.00–2.00)
Neurological (G*) 4,291 64 2.0 5,052 116 1.3 1.87(1.86–1.87)
Eyes and ears (H*) 4,914 73 2.3 4,254 97 1.1 1.23(1.23–1.23)
Blood and immune (D50-D99) 2,120 31 1.0 2,500 57 0.6 1.69(1.69–1.70)
Dermatological (L*) 1,603 24 0.8 2,176 50 0.6 2.10(2.09–2.10)
Psychiatric (F*) 1,293 19 0.6 2,035 47 0.5 2.45(2.45–2.46)
Gynaecology and Mamma (N60-N99) 664 10 0.3 469 11 0.1 1.17(1.17–1.18)
Inborn or genetic (Q*) 200 3 0.1 179 4 0.0 1.61(1.60–1.62)
Pregnancy and birth (O* & P*) 94 1 0.0 19 0 0.0 0.52(0.51–0.53)
  1. Abbreviations: COPD Chronic obstructive pulmonary disease, CoefAdj Sex- and age-adjusted coefficient, CI Confidence interval, NEC Not elsewhere classified, Factors and contacts Factors of significance for health state, and contacts to health care services—including for example check-ups and rehabilitation after disease, and admissions with negative findings ruling out suspicion of e.g., myocardial infarction or cancer